Shingrix Approved to Prevent Shingles in Immunocompromised Adults
Previously, the vaccine was only approved for adults 50 years of age and older.
Herpes Zoster Virus
Shingles: Raising Awareness and Promoting Vaccination
Despite the availability of a highly effective shingles vaccine and almost universal risk among those born before 1980, Americans are not getting vaccinated.
Immunization Schedules: Best Available Evidence for 2020
Review of the Advisory Committee Immunization Practices updates to the pediatric immunization schedule and significant revisions to the adult immunization schedule.
2008 to 2018 Saw Increase in Shingles Vaccination in Older Adults
From 2008 to 2018, there was an increase in shingles vaccination among adults aged 60 years, with variations in vaccination rates.
Adult Exposure to Chickenpox Cuts Shingles Risk
A modest but long-lasting protective effect was observed, but full protection not achieved.
Case Study: Retro-orbital Pain and Eyelid Redness
A patient presents to the emergency department complaining of headache behind her left eye and redness of the left eyelid.
Assessing Efficacy, Cost-Effectiveness of Herpes Zoster Vaccination
Researchers sought to compare the effectiveness and cost-savings of the recombinant subunit zoster vaccine with that of the live attenuated zoster vaccine in individuals aged ≥50 years.
Herpes Zoster Ophthalmicus Cases Increased in 2004 to 2012
Highest rates of HZO seen in older adults, women, and in whites vs other racial groups.
CDC Examines Safety of Recombinant Zoster Vaccine
Total of 4381 reports of adverse events during first 8 months of use; 3% were serious.
Herpes Zoster Recombinant Vaccine Seems Most Effective
However, adjuvant recombinant subunit vaccine tied to more injection site adverse events.
- Loading...
Loading...
Next post in Infectious Diseases Information Center
Loading... 
Loading...